Clinical Trial to Investigate Treatment With Photodynamic Therapy to Reduce Levels of Bacteria in Leg Ulcers

NCT00825760 | Completed Phase 2 DMC

• 1 other identifier: PPA/904W/003
• Study Type: interventional
• Target: 57
• Locations: 1 country
• Sites: 4

Brief Summary

Some leg ulcers do not seem to respond that well to the standard treatments that we currently use. One reason for this may be that there are high levels of bacteria in the ulcer which may be slowing down the rate of healing. Because we need to be careful about when we use antibiotics, this study will look at another way of killing bacteria in the ulcer. This new method involves putting a special gel on the ulcer and then shining a particular type of light (visible red light) onto the ulcer for a short period of time. In the first part of the study, a single treatment with the gel and light will be investigated. The second part of the study will compare whether or not using the treatment once a week for 12 weeks is better than placebo. Across the UK 57 people with chronic leg ulcers will be asked to take part in this study (9 in part 1 and 48 in part 2). Up to 10 sites will be involved including Cardiff University and hospitals in Bradford, Harrogate, Dundee, Hull, Plymouth and the Wirral. The research is funded by Photopharmica Ltd.

Conditions

Chronic Leg Ulcers; Wound Healing

Keywords

Antimicrobial Photodynamic Therapy; Photodynamic Therapy; PDT; Red light; Visible light; Antimicrobial; Antibacterial; Wound healing; Wound management; Leg ulcer; Chronic venous leg ulcer; Chronic wound; Wound therapy; Antimicrobial therapy

Outcome Measures

Primary Outcomes (1)

• To determine if repeat dose antimicrobial photodynamic therapy with PPA904 and PPA Lux 680 can cause a reduction in the bacterial content of chronic leg ulcers.

  Measurement of total bacterial load of the ulcer immediately before and after each treatment.

Secondary Outcomes (6)

• Measurement of the levels of specific bacteria, including anaerobes, S.aureus (MSSA and MRSA), P.aeruginosa and beta-haemolytic Streptococci in the ulcer.

  Immediately before and after each treatment.

• Measurement of the ulcer area.

  Weekly for 12 weeks post the first dose compared to pre the first dose for subjects receiving 12 doses (part 2 of the study).

• Assessment of pain.

  Pre the first dose and weekly for 12 weeks post the first dose for subjects receiving 12 doses (part 2 of the study).

• Assessment of quality of life using the Cardiff Wound Impact Schedule

  Pre the first dose and 12 weeks post the first dose for subjects receiving 12 doses (part 2 of the study).

• Measurement of PPA904 levels in peripheral blood samples.

  Pre-dose and 1h, 3h and 24h post-dose for subjects receiving 1 dose (part 1 of the study).

Study Arms (2)

1

OTHER

Single treatment

Drug: Topical PPA904 gel and light; Drug: Topical placebo gel plus light

2

OTHER

12 treatments, once weekly

Drug: Topical PPA904 gel and light; Drug: Topical placebo gel plus light

Interventions

Topical PPA904 gel and light DRUG

1; 2

Topical placebo gel plus light DRUG

1; 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects will be males or females of non-childbearing status over 18 years of age.
• Subjects will have a chronic leg ulcer with an ABPI ≥ 0.6 (measured at screening).
• Subjects will have an ulcer that has been present for at least 3 months and not more than 3 years.
• Subjects will have an ulcer with an area of 2 - 100cm2 and a maximum linear dimension of 10cm.
• Subjects will have an ulcer with a total bacterial load of ≥ 104 CFU / cm2, determined within 2 weeks before the first treatment.
• Subjects will have voluntarily signed and dated a subject Informed Consent Form (ICF).
• Subjects will be, in the opinion of the Investigator, able to understand the study, co-operate with the study procedures and be willing to return to the clinic for all the required follow-up visits.
• Subjects should be of appropriate health to participate in the study, as determined by the Investigator. This will be determined by a medical history, physical examination, 12-lead ECG and clinical laboratory evaluations.

You may not qualify if:

• Subjects under the age of 18 years of age.
• Subjects who have taken topical or systemic antibiotics during the 2 weeks prior to screening.
• Subjects who have used any anti-microbial dressing or topical antiseptic / antimicrobial or received maggot therapy during the 2 weeks prior to screening.
• Subjects who have evidence of connective tissue disorders e.g. vasculitis or rheumatoid arthritis under active treatment.
• Subjects who have any clinically significant medical condition that would impair wound healing as determined by the investigator, including uncontrolled diabetes as determined by HbA1C (\>12%) or immune disease.
• Subjects who are known to abuse alcohol or drugs currently, or to have psychological disorders that could affect follow-up care or treatment outcomes.
• Subjects who have received short course corticosteroids within 30 days prior to treatment.
• Subjects who have participated in a clinical trial of any investigational drug within 4 months prior to treatment.
• Subjects who have participated in a clinical trial of any investigational device, for example dressings, within 1 month prior to treatment.
• Subjects who have previously been treated with IMP in this trial.
• Subjects who have or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment.
• Subjects with evidence of exposed bone, tendon or facia visible around the target wound.
• Subjects with photosensitivity disorders.
• Subjects with systemic infection, whether or not related to their ulcer.
• Subjects with clinically relevant (assessed by PI) active wound infection undergoing treatment.

Sponsors & Collaborators

• Photopharmica: lead

Study Sites (4)

Department of Vascular Surgery, Bradford Royal Infirmary

Bradford, BD9 6RJ, United Kingdom

Location

Department of Wound Healing, Cardiff University

Cardiff, CF14 4XN, United Kingdom

Location

Dermatology Department, Ninewells Hospital and Medical School

Dundee, DD1 9SY, United Kingdom

Location

Dermatology Department, Harrogate District Hospital

Harrogate, HG2 7SX, United Kingdom

Location

Related Links

• The 'Wound Healing Research Unit, Cardiff University' is a collaborator for this study,

MeSH Terms

Conditions

Leg Ulcer

Interventions

Light

Condition Hierarchy (Ancestors)

Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Electromagnetic Radiation; Electromagnetic Phenomena; Magnetic Phenomena; Physical Phenomena; Optical Phenomena; Radiation; Radiation, Nonionizing

Study Officials

• Keith Harding, MBChB FRCS

  Cardiff University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 19, 2009
• First Posted: January 21, 2009
• Study Start: January 1, 2009
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: January 24, 2013

Record last verified: 2013-01

Locations

GB (4)